慢性乙型肝炎与乙型肝炎病毒携带者HLA和ApoE基因多态性差异分析*

doi:10.3969/j.issn.1672-5069.2025.01.008

摘要/Abstract

摘要： 目的分析人类白细胞抗原(HLA)和载脂蛋白E(ApoE)基因多态性与慢性乙型肝炎(CHB)发病的关系。方法 2021年4月～2024年4月我院诊治的79例CHB患者和100例慢性HBV携带者,采用直接测序法检测外周血HLA基因多态性,采用PCR法检测ApoE基因多重等位基因,根据文献进行基因分型。结果 CHB患者HLA-DQA1*0102和HLA-DRB1*15等位基因频率分别为13.9%和5.7%,显著低于HBV携带者的25.0%和14.5%,均具有显著性差异(P<0.05),而HLA-DQA1*0501、HLA-DQB1*0301、HLA-DRB1*03和HLA-DRB1*07等位基因频率分别为20.3%、31.7%、9.5%和15.8%,均显著高于HBV携带者的12.5%、20.5%、4.0%和7.5%,均具有显著性差异(P<0.05);CHB患者ApoE基因ε2/3基因型和ε2等位基因频率分别为15.2%和8.2%,显著高于HBV携带者的5.0%和3.0%,均具有显著性差异(P<0.05)。结论 CHB发病可能与HLA和ApoE基因多态性有关,携带HLA-DQA1*0102和HLA-DRB1*15等位基因可能对CHB的发生起抵制作用,而携带HLA-DQA1*0501、HLA-DQB1*0301、HLA-DRB1*03和HLA-DRB1*07等位基因或ApoE ε2等位基因可能起促进作用。

关键词: 慢性乙型肝炎, 乙型肝炎病毒携带者, 人类白细胞抗原, 载脂蛋白E, 基因多态性

Abstract: Objective The aim of this study was to explore gene polymorphisms of human leukocyte antigen (HLA) and apolipoprotein E (ApoE)in pathogenesis of chronic hepatitis B (CHB) . Methods 79 patients with CHB and 100 chronic HBV carriers were enrolled in our hospital between April 2021 and April 2024, and peripheral bloodgene polymorphisms of HLA (HLA-DQA1, HLA-DQB1, HLA-DRB1)and ApoE were detected by direct gene sequencing. Results The frequencies of HLA-DQA1*0102 and HLA-DRB1*15 allelesin patients with CHB were 13.9% and 5.7%, significantly lower than 25.0% and 14.5% (P<0.05), while the frequencies of HLA-DQA1*0501, HLA-DQB1*0301, HLA-DRB1*03 and HLA-DRB1*07 alleleswere 20.3%, 31.7%, 9.5% and 15.8%, significantly higher than 12.5%, 20.5%, 4.0% and 7.5% in HBV carriers (P<0.05); the frequencies of ε2/3 genotype and ε2 allele of ApoE gene in patients with CHB were 15.2% and 8.2%, significantly higherthan 5.0% and 3.0% in HBV carriers (P<0.05). Conclusion The gene polymorphisms of HLA and ApoE are related to pathogenesis of chronic hepatitis B. Individuals carrying HLA-DQA1*0102 and HLA-DRB1*15 alleles might protect the infection from episode, while carrying HLA-DQA1*0501, HLA-DQB1*0301, HLA-DRB1*03 and HLA-DRB1*07 allelesand/or ApoE ε2 allele might have more chances to breakout.

Key words: Hepatitis B, Hepatitis B virus carriers, Human leukocyte antigen, Apolipoprotein E, Gene polymorphism

吴继华, 石磊, 张肖, 徐震, 王铮. 慢性乙型肝炎与乙型肝炎病毒携带者HLA和ApoE基因多态性差异分析^*[J]. 实用肝脏病杂志, 2025, 28(1): 28-31.

Wu Jihua, Shi Lei, Zhang Xiao, et al. Gene polymorphisms of HLA and ApoE in pathogenesis of chronic hepatitis B[J]. Journal of Practical Hepatology, 2025, 28(1): 28-31.

参考文献

[1] 吴明山,刘振球,陈兴栋,等.全球乙型肝炎病毒基因型的分布现状.中华疾病控制杂志,2020,24(2):217-221.
[2] Wang Y, Du Z, Lawrence WR, et al. Predictinghepatitis B virus infection based on health examination data of community population. Int J Environ Res Public Health, 2019, 16(23):4842-4854.
[3] Tan M, Bhadoria AS, Cui F, et al. Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2021, 6(2):106-119.
[4] Liu Z, Derkach A, Yu KJ, et al. Patterns ofhuman leukocyte antigen class I and class II associations and cancer. Cancer Res, 2021, 81(4):1148-1152.
[5] Wang T, Shen C, Qi J, et al. Haplotype-dependent HLA-DRB1-DQB1 susceptibility to occult HBV infection in Xi'an Han population. Mol Genet Genomic Med, 2023, 11(4):2102-2110.
[6] 熊印祥,宦丽君,刘巧.代谢相关脂肪性肝病患者SLCO1B1和APOE基因多态性与脂代谢紊乱关系研究.实用肝脏病杂志,2023,26(2):206-209.
[7] Gomaa HE, Mahmoud M, Saad NE, et al. Impact of Apo E gene polymorphism on HCV therapy related outcome in a cohort of HCV Egyptian patients. J Genet Eng Biotechnol, 2018, 16(1):47-51.
[8] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2022年版).实用肝脏病杂志,2023,26(3)S18-39.
[9] 张磊,郑芳.载脂蛋白E基因分型方法学进展及其临床意义.中华检验医学杂志,2018,41(12):963-967.
[10] Chu YJ, Yang HI, Hu HH, et al. HBV genotype-dependent association of HLA variants with the serodecline of HBsAg in chronic hepatitis B patients. Sci Rep, 2023, 13(1):359-367.
[11] Li D, Zeng Z, Zhao S, et al. Human leukocyte antigen polymorphism HLA-A*24:02 is associated with acute liver disease in HBV-infected Han Chinese adults. Immunol Invest, 2023, 52(6):767-778.
[12] Zongo SV, Djigma FW, Yonli AT, et al. Association of DRB1*11 andDRB1*12 alleles of the HLA system with the evolution of the Hepatitis B virus infection in Burkina Faso. Mol Biol Rep, 2023, 50(6):5039-5047.
[13] Huang YH, Liao SF, Khor SS, et al. Large-scale genome-wide association study identifies HLA class II variants associated with chronic HBV infection: a study from Taiwan Biobank. Aliment Pharmacol Ther, 2020, 52(4):682-691.
[14] Matei HV, Vica ML, Siserman CV. Association between HLA class II alleles and hepatitis B virus infection in Transylvania, Romania. Immunol Invest, 2018, 47(7):735-744.
[15] Akcay IM, Katrinli S, Ozdil K, et al. Host genetic factors affecting hepatitis B infection outcomes: Insights from genome-wide association studies. World J Gastroenterol, 2018, 24(30):3347-3360.
[16] Karrar A, Hariharan S, Fazel Y, et al. Analysis of human leukocyte antigen allele polymorphism in patients with nonalcoholic fatty liver disease. Medicine (Baltimore), 2019, 98(32):e16704.
[17] 罗丽,王晓东,祁海滨,等.ApoE基因多态性与肥胖儿童肺炎支原体感染及反复呼吸道感染的关系.中华医院感染学杂志,2021,31(14):2224-2227.
[18] Linard M, Letenneur L, Garrigue I, et al. Interaction between APOE4 and herpes simplex virus type 1 in Alzheimer's disease. Alzheimers Dement, 2020, 16(1):200-208.
[19] Ojeda-Granados C, Panduro A, Gonzalez-Aldaco K, et al. Adherence to afish-rich dietary pattern is associated with chronic hepatitis C patients showing low viral load: implications for nutritional management. Nutrients, 2021, 13(10):3337-3351.
[20] Brito-Marques PR, Rocha-Filho PAS, Dellalibera E, et al. Cognitive changes in patient living with HIV-AIDS and apolipoprotein-Epolymorphism: is there an association? Mol Biol Rep, 2020, 47(11):8757-8762.
[21] Nascimento JCR, Pereira LC, Rêgo JMC, et al. Apolipoprotein E polymorphism influences orthotopic liver transplantation outcomes in patients with hepatitis C virus-induced liver cirrhosis. World J Gastroenterol, 2021, 27(11):1064-1075.
[22] Tréguier Y, Bull-Maurer A, Roingeard P. Apolipoprotein E, acrucial cellular protein in the lifecycle of hepatitis viruses. Int J Mol Sci, 2022, 23(7):3676-3687.
[23] Hemeda AA, Ahmad Mohamed A, Aziz RK, et al. Impact of IL10, MTP, SOD2, and APOEgene polymorphisms on the severity of liver fibrosis induced by HCV genotype 4. Viruses, 2021, 13(4):714-731.

慢性乙型肝炎与乙型肝炎病毒携带者HLA和ApoE基因多态性差异分析^*

Gene polymorphisms of HLA and ApoE in pathogenesis of chronic hepatitis B

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王常鹤, 朱璇, 邓静, 张聪颖, 赵宇, 刘芳. 超声剪切波弹性成像联合AAR、APRI和FIB-4指数诊断慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2025, 28(1): 32-35.
[2]	胡雨, 王静晖, 王瑶. 声触诊组织量化技术联合FIB-4指数和AST/ALT比值诊断慢性乙型肝炎患者肝纤维化价值研究^*[J]. 实用肝脏病杂志, 2025, 28(1): 36-39.
[3]	张天挺, 许晶, 姜正伟, 嵇卉. 丙酚替诺福韦联合肝爽颗粒治疗慢性乙型肝炎患者疗效及其对肝纤维化指标的影响^*[J]. 实用肝脏病杂志, 2024, 27(6): 820-823.
[4]	张丽, 冯禧轩, 刘飞, 延欢欢. 丙酚替诺福韦联合PEG-IFNα-2b治疗慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(6): 824-827.
[5]	何振文, 徐刚, 孟华, 陈辉, 周庆坤. 艾米替诺福韦再治疗低病毒血症的慢性乙型肝炎患者临床疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(6): 828-831.
[6]	周隽, 张忠新, 徐海燕. 可视化瞬时弹性成像与声触诊弹性成像诊断慢性乙型肝炎患者肝纤维化效能比较^*[J]. 实用肝脏病杂志, 2024, 27(6): 832-835.
[7]	彭麟, 杨春, 李兴泉. 聚乙二醇干扰素α-2b联合恩替卡韦治疗HBeAg阳性慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 677-680.
[8]	冉书容, 刘洋, 雷兰. 恩替卡韦经治的慢性乙型肝炎患者发生低病毒血症危险因素及转换TAF治疗疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 681-684.
[9]	张全乐, 赵丹, 李杰, 刘三香, 刘刚, 李亚. 富马酸替诺福韦与恩替卡韦挽救治疗拉米夫定耐药的HBeAg阴性慢性乙型肝炎患者疗效分析^*[J]. 实用肝脏病杂志, 2024, 27(4): 515-518.
[10]	薛李娜, 诸国兵, 吴琳霖, 杨小星. TAF治疗ETV经治的低病毒血症慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 519-522.
[11]	张丽, 陈雅雯, 盖琳, 邱红, 甄鑫, 常静霞. 乙型肝炎病毒/丙型肝炎病毒共同感染患者临床特征及其对抗病毒治疗应答反应研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 523-526.
[12]	虞珊珊, 张业婷, 王元鹏, 袁静文, 肖立. 慢性乙型肝炎患者血清MMP-1、MMP-2、TIMP-1和HIF-1α变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(3): 329-332.
[13]	罗良德, 任成果, 王守军, 邓颖春. 恩替卡韦联合多烯磷脂酰胆碱治疗慢性乙型肝炎合并NASH患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 333-336.
[14]	周安琪, 孟舒婷, 吴应冬, 张弦. 接受核苷(酸)类似物抗病毒的慢性乙型肝炎患者发生低病毒血症危险因素分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 337-340.
[15]	尹丹丹, 张瑞珏, 王帅, 代爱军, 周正, 张帆. 30岁以下血清ALT正常的成人慢性HBV感染者肝组织学变化研究[J]. 实用肝脏病杂志, 2024, 27(3): 341-344.